---
title: "Myriad Genetics Inc reports results for the quarter ended March 31 - Earnings Summary"
description: "Myriad Genetics Inc reported a quarterly adjusted loss of 3 cents per share for the quarter ended March 31, an improvement from a loss of 1 cent per share in the same quarter last year. Revenue decrea"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/238991605.md"
published_at: "2025-05-06T21:46:22.000Z"
---

# Myriad Genetics Inc reports results for the quarter ended March 31 - Earnings Summary

> Myriad Genetics Inc reported a quarterly adjusted loss of 3 cents per share for the quarter ended March 31, an improvement from a loss of 1 cent per share in the same quarter last year. Revenue decreased by 3.1% to $195.90 million, below analyst expectations of $200.56 million. The company reported a quarterly loss of $100 thousand and its shares fell by 13.2% this quarter. Analysts maintain a "hold" rating on the stock, with a median 12-month price target of $14.00.

-   Myriad Genetics Inc (MYGN.OQ) reported a quarterly adjusted loss of 3 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -1 cents. The mean expectation of seventeen analysts for the quarter was for a loss of 6 cents per share. Wall Street expected results to range from -8 cents to -3 cents per share.
    
-   Revenue fell 3.1% to $195.90 million from a year ago; analysts expected $200.56 million.
    
-   Myriad Genetics Inc’s reported EPS for the quarter was breakeven results​.
    
-   The company reported a quarterly loss of $100 thousand.
    
-   Myriad Genetics Inc shares had fallen by 13.2% this quarter and lost 43.8% so far this year. FORECAST CHANGES
    
-   The mean earnings estimate of analysts had fallen by about 340.1% in the last three months.​
    
-   In the last 30 days, one analyst negatively revised an earnings estimate RECOMMENDATIONS
    
-   The current average analyst rating on the shares is “hold” and the breakdown of recommendations is 7 “strong buy” or “buy,” 6 “hold” and 4 “sell” or “strong sell.” The average consensus recommendation for the medical equipment, supplies & distribution peer group is also “hold”
    
-   Wall Street’s median 12-month price target for Myriad Genetics Inc is $14.00 This summary was machine generated from LSEG data May 6 at 09:46 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
    

### MISSED

Mar. 31 2025 -0.06 -0.03 Beat

Dec. 31 2024 0.03 0.03 Met

Sep. 30 2024 0.02 0.06 Beat

Jun. 30 2024 -0.01 0.05 Beat

### Related Stocks

- [MYGN.US - Myriad Genetic](https://longbridge.com/en/quote/MYGN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 萬基遺傳計劃在 2026 年 3 月推出用於乳腺癌的精準 MRD 檢測 | 萬基遺傳公司將在 2026 年 3 月推出其精準 MRD™檢測，用於乳腺癌的臨牀應用，標誌着從研究階段向臨牀使用的過渡。初期將重點關注乳腺癌，計劃在年內擴展到結直腸癌和腎癌，並可能在 2027 年涉及卵巢癌和子宮內膜癌。來自 MONITOR | [Link](https://longbridge.com/en/news/273858602.md) |
| 萬基遺傳預計 2025 年的收入將在 8.22 億美元到 8.24 億美元之間 | 萬基遺傳公司（Myriad Genetics Inc.）宣佈了 2025 年第四季度和全年的初步未經審計的財務結果，預計全年總收入將在 8.22 億至 8.24 億美元之間。第四季度的收入預計將在 2.07 億至 2.09 億美元之間。該公 | [Link](https://longbridge.com/en/news/272277739.md) |
| Myriad Uranium 和 Rush Rare Metals 簽署了最終合併協議，根據該協議，Myriad 將收購 Rush \| MYRUF 股票新聞 | Myriad Uranium Corp. 和 Rush Rare Metals Corp. 已簽署最終合併協議，Myriad 將以 1 股 Rush 股票兑換 0.5405 股 Myriad 股票的比例收購 Rush 的 100% 普通股。 | [Link](https://longbridge.com/en/news/275897248.md) |
| Raymond James 繼續對萬基遺傳 (MYGN) 維持買入評級 | Raymond James 分析師 Andrew Cooper 對 Myriad Genetics (MYGN) 維持了買入評級，目標價為 8.00 美元。該分析師的平均回報率為 -1.8%，成功率為 44.44%。根據 TipRanks  | [Link](https://longbridge.com/en/news/272395885.md) |
| 萬基遺傳宣佈 2025 年第四季度和全年部分初步財務業績，併發布 2026 年全年財務指引 | 1 月 12 日（路透社）- 萬基遺傳公司：萬基遺傳宣佈 2025 財年第四季度和全年初步財務結果，並介紹 2026 財年財務指引。萬基遺傳公司 - 預計 2025 財年第四季度收入在 2.07 億美元至 2.09 億美元之間。萬基遺傳公司 | [Link](https://longbridge.com/en/news/272278345.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.